Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC
Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.
Related Articles
Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Ribociclib Combo Produces Similar pCR to Chemo in HR+ Breast Cancer
Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.
First-line Disitamab Vedotin/Toripalimab Ups Survival in HER2+ mUC
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma
Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.
Retifanlimab Receives FDA Approval for Advanced Anal Cancer
Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.
Injection Time Can Encourage Bonding During Myeloma Care
The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.
Bevacizumab Combo Appears Effective, Safe for Older Patients With mCRC
The addition of bevacizumab to capecitabine produced favorable efficacy and safety data for older patients with metastatic colorectal cancer.
Telisotuzumab Vedotin-tllv Given Accelerated Approval for NSCLC
Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression.
Belzutifan Granted FDA Approval for Pheochromocytoma or Paraganglioma
Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma.